What the Biggest ASCO Cancer Research Updates Could Mean for Patients
ADC Provides Patients with Better Results Even After Subsequent Therapy for Advanced Triple-Negative Breast Cancer
Comprehensive Cancer Care for the Doral Community
RAS(ON) Inhibitor Doubles Median Overall Survival in Results of Phase 3 Trial for Patients with Metastatic Pancreatic Cancer
Addition of Mezigdomide to Standard Therapy Significantly Improves Outcomes in Relapsed Refractory Multiple Myeloma
Dana-Farber Study Finds Stage IV Breast Cancer Increasing in Incidence and Proportion Over the Last Decade
AI Tool Could Speed Discovery of New Cancer Drug Targets
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy (GAIN-BCG)
Adaptive Radiation Therapy for Men with Intermediate- or High-Risk Prostate Cancer (DE-CART)
Dana-Farber’s Dr. Toni Choueiri Elected to the Association of American Physicians
Dana-Farber Phase 1 Study Explores Toxicity Reduction in Combination of Trastuzumab Deruxtecan and Olaparib in Advanced HER2-Expressing Malignancies
Stuart Orkin Awarded Breakthrough Prize in Life Sciences
Dana-Farber Researchers Presented More Than 50 Research Studies at American Association for Cancer Research Annual Meeting 2026
Immune Activity Shift a Key Early Step in Breast Cancer Formation
Dana-Farber Researchers Receive AACR 2026 Scientific Achievement Awards
Showing 1 - 15 of 1046 results
Previous| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ...70 |Next
Cancer
Cardiology
Gastroenterology
Neurology
OBGYN
Orthopedics
Pediatrics
BroadcastMed News
Dermatology
Diabetes & Endocrinology
Infectious Diseases
Ophthalmology
Optometry
Otolaryngology
Pulmonology
Surgery
Urology
About
Solutions
Resources
Contact
person Sign In / Create Account
